STOCKS TELEGRAPH

Tag: Greenwich LifeSciences

  • Why is Greenwich LifeSciences, Inc. (GLSI) stock popping high in Pre-Market trading?

    Why is Greenwich LifeSciences, Inc. (GLSI) stock popping high in Pre-Market trading?

    Greenwich LifeSciences, Inc. (GLSI), a clinical-stage biopharmaceutical company, today reported the Robust Immune Response Phase IIb Data after which the GLSI stock price surged by 26.73% to reach $64.00 a share as of this writing. Today’s news of Greenwich has made the momentum for GLSI stock which was down at the previous trading session and closed with a 1.52% drop. Let’s try to figure out more about GLSI stock.

    What’s happening?

    Greenwich LifeSciences is mainly focused on the development of GP2 which is the immunotherapy to treat or prevent breast cancer in patients having a history of surgery. GLSI announced the Phase IIb clinical trial Data following the 5 years at the 2021 AACR Annual Meetingwhich supports the previously reported outcome of 0% Metastatic Breast Cancer Recurrences. The AACR published the final 5-year immune response data today and graphical posters of immune response data will be published on Saturday, April 10, 2021.

    The GP2 manufacturing is expected to complete in the period between the second and third quarter of 2021 and the presentation of the updated design of the Phase III clinical trial will be in the period between the third and fourth quarter of 2021.

    A deep look at Greenwich:

    Research shows that one out of eight women develops breast cancer, and one out of 833 men develops breast cancer in the United States and Greenwich LifeSciences is acting as the leader in the battle against breast cancer. Before December 2020, GLSI stock share price was not higher than $6 despite so much effort by the management, but the month of December did wonders for the GLSI stock as its per-share price skyrocketed to $70 as of December 10, 2020, and then the GLSI lowered back to $36 at the end of 2020.

    Conclusion:

    GLSI stock price is rising in the pre-market today in response to the reporting of data for robust immune response. GLSI stock has developed significantly for the last few months due to its continuous efforts against breast cancer. In a nutshell GLSI stock can be a good bet in the long run.

  • Top key players of Biotech Industry

    Top key players of Biotech Industry

    It is evident with so many people focused on COVID-19 that biotech stocks with coronavirus vaccines and treatments have gained a lot of attention.

    The Pfizer and BioNTech vaccine is developed on mRNA science, more straightforward, quicker, and cheaper to produce than standard vaccines. Even so, amid the enormous capital and expertise of Pfizer, the large pharmaceutical firm has failed to reach the production goals it initially set for the vaccine, needing to cut the original 100 million doses in 2020 to 50 million last month.

    The development issues are not restricted to vaccines for Covid-19 either. The FDA authorized the use of antibody drugs to treat Covid-19 last month, for example, complicated to develop. Other indications include diagnostics and cell therapies are in development. Flowing are the key performers from the Biotech sectors in yesterday’s market session.

    Xenetic Biosciences Inc. (NASDAQ:XBIO) shares were trading up 193.52% at $3.17 at the time of writing on Wednesday following declaration that it saw positive data from its partner PJSC Pharmsynthez about its pivotal Phase 3 clinical study leveraging PolyXen to develop a treatment for anemia in patients with chronic kidney disease (CKD).

    Xenetic Biosciences Inc. (NASDAQ:XBIO) share price went from a low point around $0.44 to briefly over $1.85 in past 52 weeks, though shares have since pulled back to $3.17. XBIO market cap has remained high, hitting $20.45M at the time of writing, giving it price-to-sales ratio of more than 60.

    If we look at the recent analyst rating XBIO, Maxim Group initiated coverage on XBIO shares with a Buy rating.

    Moderna Inc. (MRNA) last closed at $156.59, in a 52-week range of $17.68 to $178.50. The healthcare firm recently declared that the Swiss Federal Government has increased its confirmed order commitment from 4.5 million to 7.5 million doses of Moderna’s vaccine candidate against COVID-19, mRNA-1273. Analysts have a consensus price target of $122.60.

    GeoVax Labs Inc. (GOVX) stock soar by 79.06% to $5.73. The company on November 30, 2020 reported license agreement with NIH to support continued advancements in vaccine development. The most recent rating by Maxim Group, on November 19, 2020, is at a Buy.

    Intec Pharma Ltd (NASDAQ:NTEC) Shares headed rising, higher as much as 34.10% after declaring that it has entered into a feasibility agreement with GW Research Limited, London, U.K. to explore using the Accordion Pill (AP) platform for an undisclosed research program.. The most recent rating by Ladenburg Thalmann, on December 09, 2020, is at a Buy.

    Atossa Therapeutics Inc. (NASDAQ:ATOS) fall -39.03% after losing more than -$0.56 on Wednesday after the company reported pricing of $20.0 million underwritten public offering.

    Sorrento Therapeutics Inc. (SRNE) last closed at $8.21, in a 52-week range of $1.55 to $19.39. The company reported that it received US FDA clearance to proceed with Phase 1 Clinical Trials for STI-2020 (COVI-AMG) in healthy volunteers and in newly diagnosed COVID-19 Patients.

    Greenwich LifeSciences Inc. (GLSI) stock soar by 998.35% to $57.10 after reporting the publication of a poster for the GP2 Phase IIb clinical trial final efficacy analysis at the San Antonio Breast Cancer Symposium in a virtual format.

    Jaguar Health Inc. (NASDAQ:JAGX) Shares headed falling, lower as much as -11.45%. The most recent rating by Rodman & Renshaw, on July 11, 2017, is at a Buy.

    Lipocine Inc. (NASDAQ:LPCN) fall -21.43% after losing more than -$0.36 on Wednesday following the announcement from the company that the U.S. Food and Drug Administration has granted tentative approval to TLANDO

    Tonix Pharmaceuticals Holding Corp. (TNXP) last closed at $0.64, in a 52-week range of $0.39 to $2.46. On December 3, 2020, the firm declared positive phase 3 RELIEF study results for TNX-102 SL 5.6 mg in Fibromyalgia.

    SELLAS Life Sciences Group Inc. (SLS) stock soar by 73.17% to $6.39. The company on December 7, 2020 revealed an exclusive license agreement with 3D Medicines for development and commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China. The most recent rating by Oppenheimer, on November 01, 2018, is at an Outperform.

    AIkido Pharma Inc. (NASDAQ:AIKI) Shares headed rising, higher as much as 4.07% after declaring the publication of positive results from its Artificial Intelligence/Machine Learning Sponsored Research Program in the field of Pancreatic Cancer.

    Celsion Corporation (NASDAQ:CLSN) rose 12.90% after gaining more than $0.08 on Wednesday.

    ADMA Biologics Inc. (ADMA) last closed at $2.22, in a 52-week range of $1.45 to $4.65. The firm recently announced $100 million credit facility loan amendment with perceptive advisors.

    Onconova Therapeutics Inc. (ONTX) stock soar by 1.75% to $0.32. On November 23, 2020, the company reported the filing of an investigational new drug application for Multi-kinase CDK4/6 Inhibitor ON 123300. The most recent rating by H.C. Wainwright, on March 01, 2018, is at a Buy.

  • The reason why Greenwich LifeSciences, Inc. (Nasdaq: GLSI) shares jumped in the late hours yesterday

    The reason why Greenwich LifeSciences, Inc. (Nasdaq: GLSI) shares jumped in the late hours yesterday

    Greenwich LifeSciences, Inc. (Nasdaq: GLSI) stock jumped vigorously in the post-market trading hours, as the shares jumped 31.75% to reach $75.23 following, a clinical-stage biotech corporation focusing on improving GP2 and immunotherapy to reduce breast cancer infections in patients that have already undergone surgery, revealed the publishing of a poster for the GP2 Phase IIb clinical trial final efficacy study. An audio track giving an outline was also documented by the CEO of Greenwich LifeSciences, Snehal Patel. It is available to view on the organization’s website and the conference website for members.

    The poster illustrates the final 5-year follow-up curves of disease-free survival analyzing the decline of breast cancer recurrence for patients in both HER2/neu 3+ (Figure 1) and HER2/neu 1-2+ (Figure 2) cohorts, comprising demographics (Table 1) for cancer level, hormone receptor status, node status, and previous chemotherapy, radiation, endocrine therapy, or trastuzumab treatment (Herceptin).